Cargando…
Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia
OBJECTIVES: To determine the status of the HER2 amplification in Breast cancer performed in peripheral laboratories in Colombia by immunohistochemistry and its comparison with central laboratories and the FISH status. METHODS: Four thousand one hundred and five cases referred for the determination o...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Universidad del Valle
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002025/ https://www.ncbi.nlm.nih.gov/pubmed/24892456 |
_version_ | 1782313774831632384 |
---|---|
author | Plata, Adriana Torres, Maria Mercedes López, Rocío Andrade, Rafael E |
author_facet | Plata, Adriana Torres, Maria Mercedes López, Rocío Andrade, Rafael E |
author_sort | Plata, Adriana |
collection | PubMed |
description | OBJECTIVES: To determine the status of the HER2 amplification in Breast cancer performed in peripheral laboratories in Colombia by immunohistochemistry and its comparison with central laboratories and the FISH status. METHODS: Four thousand one hundred and five cases referred for the determination of the HER2 status by FISH and/or IHQ to the Department of Pathology of the Fundacion Santa Fe were studied. The analysis included correlation between the IHQ HER2 score submitted by the peripheral laboratory (PL), the HER2 score emitted in the CL and the FISH studies performed in the central laboratory (CL). RESULTS: Two thousand five hundred and eight HER2 IHQ studies were performed in the (CL), using the Dako Herceptest. With the following results: 68.2 % negative (0-1+); 16,4% indeterminate (2+); 15.3% 3+ and 2.3 % not adequate. 1360/ 1719 cases studied by FISH came from the (PL), and 329 (19.1%) from the (CL). Comparing the IHQ score emitted by the PL and the positive FISH status showed: 6/28 0+ were positive (21. 4%); 7/31 1+ (22. 5%); 397/1240 2+ (32.8%) and 74/91 3+ (81. 3%). In the CL the results were 1/9 0+ (11.1%); 3/18 1+ (16.7%); 154/292 2+ (53%); and 9/9 3+ (100%). Only 1/4 negative cases (0/1+) was in house. CONCLUSION: The false negative rate (22%), and false positive results (18.7%), of the HER2 status performed by IHQ in peripheral laboratories in Colombia is unacceptable high as well as the inadequacy of tissue indicating that pre-analytical factors have to be improved in Colombia in order to get optimal results. |
format | Online Article Text |
id | pubmed-4002025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Universidad del Valle |
record_format | MEDLINE/PubMed |
spelling | pubmed-40020252014-06-02 Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia Plata, Adriana Torres, Maria Mercedes López, Rocío Andrade, Rafael E Colomb Med (Cali) Original Article OBJECTIVES: To determine the status of the HER2 amplification in Breast cancer performed in peripheral laboratories in Colombia by immunohistochemistry and its comparison with central laboratories and the FISH status. METHODS: Four thousand one hundred and five cases referred for the determination of the HER2 status by FISH and/or IHQ to the Department of Pathology of the Fundacion Santa Fe were studied. The analysis included correlation between the IHQ HER2 score submitted by the peripheral laboratory (PL), the HER2 score emitted in the CL and the FISH studies performed in the central laboratory (CL). RESULTS: Two thousand five hundred and eight HER2 IHQ studies were performed in the (CL), using the Dako Herceptest. With the following results: 68.2 % negative (0-1+); 16,4% indeterminate (2+); 15.3% 3+ and 2.3 % not adequate. 1360/ 1719 cases studied by FISH came from the (PL), and 329 (19.1%) from the (CL). Comparing the IHQ score emitted by the PL and the positive FISH status showed: 6/28 0+ were positive (21. 4%); 7/31 1+ (22. 5%); 397/1240 2+ (32.8%) and 74/91 3+ (81. 3%). In the CL the results were 1/9 0+ (11.1%); 3/18 1+ (16.7%); 154/292 2+ (53%); and 9/9 3+ (100%). Only 1/4 negative cases (0/1+) was in house. CONCLUSION: The false negative rate (22%), and false positive results (18.7%), of the HER2 status performed by IHQ in peripheral laboratories in Colombia is unacceptable high as well as the inadequacy of tissue indicating that pre-analytical factors have to be improved in Colombia in order to get optimal results. Universidad del Valle 2013-06-30 /pmc/articles/PMC4002025/ /pubmed/24892456 Text en Copyright: © 2013 Universidad del Valle. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Plata, Adriana Torres, Maria Mercedes López, Rocío Andrade, Rafael E Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia |
title | Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia |
title_full | Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia |
title_fullStr | Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia |
title_full_unstemmed | Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia |
title_short | Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia |
title_sort | determination of the her2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in colombia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002025/ https://www.ncbi.nlm.nih.gov/pubmed/24892456 |
work_keys_str_mv | AT plataadriana determinationoftheher2amplificationstatusbyinsitufluorescenthybridizationandconcordancewithimmunohistochemistryforbreastcancersamplesincolombia AT torresmariamercedes determinationoftheher2amplificationstatusbyinsitufluorescenthybridizationandconcordancewithimmunohistochemistryforbreastcancersamplesincolombia AT lopezrocio determinationoftheher2amplificationstatusbyinsitufluorescenthybridizationandconcordancewithimmunohistochemistryforbreastcancersamplesincolombia AT andraderafaele determinationoftheher2amplificationstatusbyinsitufluorescenthybridizationandconcordancewithimmunohistochemistryforbreastcancersamplesincolombia |